Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

YM BioSciences-Cytopia merger complete

YM BioSciences Inc., announced that the merger of Cytopia Limited, the Australian biopharmaceutical company, into YM under a Scheme of Arrangement, has been concluded.

1 Feb 2010

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Abbott announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.

1 Feb 2010

Patients with rare autoimmune disease produce antibodies that disarm immune proteins

Two studies published online on February 1 in the Journal of Experimental Medicine (www.jem.org) reveal that patients with a rare autoimmune disease produce antibodies that attack microbe-fighting immune proteins called cytokines.

1 Feb 2010

New testing method for early detection of cancer

A new testing method is being developed to detect cancer soon after the tumor has formed. It will identify characteristic substances in the blood which accompany a certain type of tumor. The first steps in the development have already been completed.

1 Feb 2010

Clinical results of MedImmune's pivotal trial for motavizumab published

MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics: Official Journal of the American Academy of Pediatrics.

30 Jan 2010

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

30 Jan 2010

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities.

29 Jan 2010

New understanding of CD44 receptor's role in immune cell survival

Investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a new way the cell surface protein, CD44, helps specific T helper (Th1) cells develop immunologic memory.

29 Jan 2010

Experimental vaccine protects mice and monkeys against chikungunya virus

An experimental vaccine developed using non-infectious virus-like particles (VLP) has protected macaques and mice against chikungunya virus, a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain, researchers at the National Institutes of Health have found.

29 Jan 2010

NHMRC awards Development Grant to speed up chronic wound treatment

A new treatment that could one day benefit burns victims, diabetes sufferers and the elderly - by fast tracking the healing of chronic wounds - has taken another step towards commercialization.

29 Jan 2010

Nontoxic drug halts and reverses rheumatoid arthritis

A researcher from Northwestern University Feinberg School of Medicine has invented a novel way to halt and even reverse rheumatoid arthritis. He developed an imitation of a suicide molecule that floats undetected into overactive immune cells responsible for the disease.

29 Jan 2010

Baxter International reports net income of $572M for the fourth-quarter of 2009

Baxter International Inc. today reported strong performance for the fourth quarter of 2009, and provided its financial outlook for the first quarter and full-year 2010.

From Baxter International Inc. 28 Jan 2010

Repligen announces five-year supply agreement for recombinant Protein A with GE Healthcare Bio-Sciences

Repligen Corporation announced today that it has extended its longstanding relationship with GE Healthcare Bio-Sciences AB by entering into a five-year supply agreement for recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, a highly successful class of biopharmaceutical. Repligen is the world's leading supplier of recombinant Protein A and has manufactured recombinant Protein A for GE Healthcare for more than 10 years.

28 Jan 2010

Blocking action of key protein boosts immune 'memory' to prevent or clear viral infection

Researchers at The Scripps Research Institute have discovered a potential new way to stimulate the immune system to prevent or clear a viral infection. By blocking the action of a key protein in the mouse immune system, they were able to boost immune "memory" in those mice-work that may one day help doctors increase the effectiveness of human vaccines designed to prevent viral infections.

28 Jan 2010

Merck receives marketing authorization for ELONVA

Merck & Co., Inc., which operates outside the U.S. and Canada as MSD, today announced the European Commission (EC) approval of ELONVA® (corifollitropin alfa injection). ELONVA is indicated for controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (ART) program.

28 Jan 2010

Elevated cytokine levels are early indicator of rheumatoid arthritis

Researchers from University Hospital in Umea, Sweden, have identified several cytokines, cytokine-related factors, and chemokines that increase significantly prior to rheumatoid arthritis (RA) disease onset. These findings confirm those of earlier studies which suggest that the risk of developing RA can be predicted and disease progression may be prevented.

28 Jan 2010

Inovio Biomedical unveils new clinical-grade, miniaturized electroporation device

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, today unveiled its new clinical-grade, miniaturized electroporation device designed to be an easy-to-use, portable delivery product for DNA vaccines.

28 Jan 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

Juvaris BioTherapeutics completes second close on its Series B equity financing

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed a second close on its Series B equity financing of up to $25 million. The additional equity investment came from an undisclosed strategic corporate investor who joins SV Life Sciences and Kleiner Perkins Caufield & Byers in the round.

27 Jan 2010

TE can be accurately performed in majority of NAFLD patients to exclude advanced fibrosis

Researchers from France and Hong Kong determined that transient elastography (TE), a noninvasive, ultrasonic imaging modality, can be accurately performed in the majority of patients with nonalcoholic fatty liver disease (NAFLD) to exclude advanced fibrosis. Full findings of this study, funded by the Chinese University of Hong Kong, appear in the February issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

27 Jan 2010